Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis

被引:90
作者
Kröger, N [1 ]
Zabelina, T [1 ]
Schieder, H [1 ]
Panse, J [1 ]
Ayuk, F [1 ]
Stute, N [1 ]
Fehse, N [1 ]
Waschke, O [1 ]
Fehse, B [1 ]
Kvasnicka, HM [1 ]
Thiele, J [1 ]
Zander, A [1 ]
机构
[1] Univ Hosp Cologne, Inst Pathol, Cologne, Germany
关键词
myelofibrosis; reduced-intensity conditioning; donor lymphocyte infusion; graft-versus-host disease; graft failure;
D O I
10.1111/j.1365-2141.2005.05373.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A prospective pilot study was performed to evaluate the effect of reduced-intensity conditioning with busulphan (10 mg/kg), fludarabine (180 mg/qm) and anti-thymocyte globulin followed by allogeneic stem cell transplantation from related (n = 8) and unrelated donors (n = 13) in 21 patients with myelofibrosis. The median age of the patients was 53 years (range, 32-63). No primary graft failure occurred. The median time until leucocyte (>1.0 x 10(9)/l) and platelet (>20 x 10(9)/l) engraftment was 16 (range, 11-26) and 23 d (range, 9-139) respectively. Complete donor chimaerism on day 100 was seen in 20 patients (95%). Acute graft-versus-host disease (GvHD) grades II-IV and III/IV occurred in 48% and 19% of cases and 55% of the patients had chronic GvHD. Treatment-related mortality was 0% at day 100 and 16% [95% confidence interval (CI): 0-32%] at 1 year. Haematological response was seen in 100% and complete histopathological remission was observed in 75% of the patients and 25% of the patients showed partial histopathological remission with a continuing decline in the grade of fibrosis. After a median follow-up of 22 months (range, 4-59), the 3-year estimated overall and disease-free survival was 84% (95% CI: 67-100%).
引用
收藏
页码:690 / 697
页数:8
相关论文
共 39 条
[1]   The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia [J].
Barosi, G ;
Ambrosetti, A ;
Finelli, C ;
Grossi, A ;
Leoni, P ;
Liberato, NL ;
Petti, MC ;
Pogliani, E ;
Ricetti, M ;
Rupoli, S ;
Visani, G ;
Tura, S .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 104 (04) :730-737
[2]   A PROGNOSTIC CLASSIFICATION OF MYELOFIBROSIS WITH MYELOID METAPLASIA [J].
BAROSI, G ;
BERZUINI, C ;
LIBERATO, LN ;
COSTA, A ;
POLINO, G ;
ASCARI, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (04) :397-401
[3]  
BAUERMEISTER DE, 1971, AM J CLIN PATHOL, V56, P24
[4]   REGIMEN-RELATED TOXICITY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION [J].
BEARMAN, SI ;
APPELBAUM, FR ;
BUCKNER, CD ;
PETERSEN, FB ;
FISHER, LD ;
CLIFT, RA ;
THOMAS, ED .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (10) :1562-1568
[5]  
BELLUCCI S, 1986, CANCER, V58, P2440, DOI 10.1002/1097-0142(19861201)58:11<2440::AID-CNCR2820581115>3.0.CO
[6]  
2-Y
[7]  
Byrne JL, 2000, BRIT J HAEMATOL, V108, P430
[8]   Complete remission of idiopathic myelofibrosis following donor lymphocyte infusion after failure of allogeneic transplantation: demonstration of a graft-versus-myelofibrosis effect [J].
Cervantes, F ;
Rovira, M ;
Urbano-Ispizua, A ;
Rozman, M ;
Carreras, E ;
Montserrat, E .
BONE MARROW TRANSPLANTATION, 2000, 26 (06) :697-699
[9]   Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups [J].
Cervantes, F ;
Barosi, G ;
Demory, JL ;
Reilly, J ;
Guarnone, R ;
Dupriez, B ;
Pereira, A ;
Montserrat, E .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 102 (03) :684-690
[10]   Stem cell transplantation for myelofibrosis: a report from two Canadian centers [J].
Daly, A ;
Song, K ;
Nevill, T ;
Nantel, S ;
Toze, C ;
Hogge, D ;
Forrest, D ;
Lavoie, J ;
Sutherland, H ;
Shepherd, J ;
Hasegawa, W ;
Lipton, J ;
Messner, H ;
Kiss, T .
BONE MARROW TRANSPLANTATION, 2003, 32 (01) :35-40